Exemestane

Exemestane (brand name Aromasin) is best known as a breast cancer treatment for postmenopausal women, lowering estrogen by blocking the aromatase enzyme. Unlike anastrozole and letrozole, it is steroidal, binding the enzyme irreversibly so its effect lasts until the body makes new enzyme. It's a small-molecule oral drug, not a peptide. It's FDA-approved for that breast-cancer use; use in men is off-label.

Exemestane is used mainly to treat breast cancer in postmenopausal women, and studied off-label in men to control estrogen. It's FDA-approved for the breast-cancer use. In trials in postmenopausal women it improved outcomes after tamoxifen (the IES trial) and reduced breast cancer incidence in higher-risk women (the MAP.3 prevention trial). For men's-health uses such as managing estrogen on testosterone therapy, there are no published randomized trials of exemestane specifically, so that use is extrapolated from the breast-cancer data and the evidence in men is limited.

FDA-approved (Aromasin, originally Pharmacia, now Pfizer; NDA 020753, originally approved October 21, 1999, for advanced postmenopausal breast cancer; subsequent approvals for adjuvant treatment of postmenopausal women with estrogen-receptor-positive early breast cancer who have received 2-3 years of tamoxifen). Generic exemestane has been widely available since 2011 (US patent expiry). FDA-approved indications are exclusively in postmenopausal women with breast cancer; all use in men is off-label, paralleling the Anastrozole and Letrozole regulatory pattern. Listed in the WADA 2026 Prohibited List under S4.1 (Aromatase Inhibitors) as a Specified Substance — explicitly named alongside anastrozole, letrozole, and aminoglutethimide.

Exemestane is a prescription-only medication, FDA-approved only for breast cancer in postmenopausal women; it is banned in WADA-tested sport, and aromatase inhibitors can accelerate bone loss with longer use. VialWise is a research and educational reference, not medical advice — consult a licensed professional.

⚠️ For research and educational purposes only. Exemestane is FDA-approved for postmenopausal breast cancer indications, but all use in men is off-label. Information in this entry is informational, not medical advice. Always confirm dose calculations and consult appropriate professional guidance before any protocol decisions, particularly for off-label men's-health use.

⚠️ Mechanistically distinct from anastrozole and letrozole. Exemestane is a steroidal, irreversible (suicide) aromatase inhibitor — chemically derived from the natural aromatase substrate androstenedione, it binds covalently to the aromatase enzyme's active site and permanently inactivates it. New aromatase activity requires synthesis of new enzyme protein. This is fundamentally different from anastrozole and letrozole (both nonsteroidal, reversible) — the practical implications include: (1) exemestane's effect persists beyond the drug's plasma elimination, with aromatase recovery dependent on enzyme protein turnover (~3–7 days); (2) exemestane has weak androgenic activity from its steroidal backbone, in contrast to the nonsteroidal AIs which are pharmacologically inert outside aromatase inhibition; (3) cross-resistance between the AI classes is incomplete — exemestane retains some activity in tumors that have progressed on anastrozole or letrozole. Researchers should not treat exemestane as interchangeable with the nonsteroidal AIs in the AI cluster.

⚠️ Off-label men's-health use is supported by mechanism but not by RCT-grade efficacy data. No randomized controlled trial of exemestane in male hypogonadism, TRT-adjunct estrogen management, or AAS-cycle estrogen management has been published. The off-label use case extrapolates from (a) the breast cancer adjuvant data showing reliable estradiol suppression and (b) the general AI-class men's-health rationale also covered in the [Anastrozole](./anastrozole.md) and [Letrozole](./letrozole.md) entries. The 2013 Loves et al. RCT in obese hypogonadal men used letrozole specifically (not exemestane); the exemestane-specific clinical evidence for non-cancer men's-health use is research-community-attributed rather than RCT-grade.

⚠️ Mild androgenic activity is a notable distinguishing feature in men's-health context. Because exemestane is a steroidal compound derived from androstenedione, its metabolites (notably 17-hydroxyexemestane) have weak androgenic activity at androgen receptors. This produces a small, measurable testosterone-like signal that the nonsteroidal AIs (anastrozole, letrozole) lack. The clinical magnitude is modest and the practical implication for men's-health use is uncertain — but researchers selecting between exemestane and a nonsteroidal AI should be aware that exemestane is not pharmacologically inert beyond aromatase inhibition.

⚠️ WADA-prohibited at all times under S4.1. Exemestane is listed by name on the 2026 WADA Prohibited List under Section S4.1 (Aromatase Inhibitors).[⁵] Aromatase inhibitors are Specified Substances under WADA. Researchers competing in WADA-tested sport should not use exemestane.

Exemestane (FCE-24304, brand name Aromasin) is a third-generation steroidal aromatase inhibitor developed by Pharmacia (now Pfizer) in the 1990s. The compound is a 6-methylene-androstadiene derivative — chemically a modified version of the natural aromatase substrate androstenedione. This structural similarity is the basis for its irreversible mechanism: exemestane binds the aromatase enzyme's active site as if it were the natural substrate, but its 6-methylene group reacts covalently with a critical active-site residue, permanently inactivating the enzyme. Recovery of aromatase activity requires synthesis of new enzyme protein over ~3–7 days, which produces functional aromatase suppression that outlasts the drug's plasma half-life. The compound was FDA-approved (NDA 020753) in October 1999 for advanced postmenopausal breast cancer; the adjuvant indication followed in 2005 based on the Intergroup Exemestane Study (IES) results.

FDA-approved indication and the IES/TEAM trials. Exemestane's pivotal Phase 3 trial in adjuvant breast cancer was the Intergroup Exemestane Study (IES), a randomized double-blind trial of exemestane versus continued tamoxifen in postmenopausal women who had completed 2–3 years of adjuvant tamoxifen.[¹] The 2004 NEJM publication of the primary results (Coombes et al., 25+ author byline including the IES Investigators, n=4,742) reported that switching to exemestane reduced the hazard of disease-free-survival events by 32% (HR 0.68) compared with continuing tamoxifen, with a 4.7% absolute disease-free-survival benefit at 3 years post-randomization. Severe toxic effects of exemestane were rare. The IES results — alongside the BIG 1-98 letrozole results from 2005 — established the AI class (including exemestane) as superior to tamoxifen monotherapy in adjuvant therapy of postmenopausal hormone-receptor-positive breast cancer.

Chemoprevention — the MAP.3 trial. A separate pivotal trial established exemestane's role in primary breast cancer prevention. The ncic ctg map.3 trial (2011, Goss et al., 20+ author byline, n=4,560) was a randomized placebo-controlled trial of exemestane in postmenopausal women at moderately increased breast cancer risk.[³] After 35 months median follow-up, exemestane reduced annual incidence of invasive breast cancer by 65% (HR 0.35) and combined invasive plus DCIS by 53% (HR 0.47). Adverse events were comparable to placebo with no significant differences in skeletal fractures, cardiovascular events, or quality of life. MAP.3 established exemestane as one of the two AIs (alongside anastrozole via ibis-II) with primary prevention indication; letrozole has not been studied in a comparable chemoprevention trial.

Mechanism — comparison to nonsteroidal AIs. All three FDA-approved third-generation AIs act on the aromatase enzyme but exemestane's irreversible mechanism is the central pharmacological distinction. Nonsteroidal AIs (anastrozole, letrozole) bind the heme iron of the active site reversibly — pharmacological effect tracks plasma drug concentration; aromatase activity recovers as the drug clears. Exemestane binds the active site irreversibly via its 6-methylene group; pharmacological effect persists until new enzyme protein is synthesized (~3–7 days). Practical implications include: (a) exemestane's once-daily dosing produces persistent aromatase suppression even with imperfect adherence; (b) cross-resistance with the nonsteroidal AIs is incomplete — exemestane retains activity in some tumors that have progressed on anastrozole or letrozole; (c) the steroidal backbone produces weak androgenic activity at androgen receptors via metabolites (notably 17-hydroxyexemestane), which the nonsteroidal AIs lack. The clinical magnitude of the androgenic effect at standard doses is modest but measurable.

Off-label men's-health use. As with anastrozole and letrozole, exemestane's mechanism of suppressing estradiol synthesis from testosterone substrate makes it relevant to men's-health protocols requiring estrogen-management — TRT, AAS cycles, obesity-related hypogonadism. The clinical evidence base for exemestane specifically in men's health is thinner than for letrozole or anastrozole. No published RCT has evaluated exemestane in male hypogonadism, TRT-adjunct estrogen management, or AAS-cycle estrogen management. The off-label use case extrapolates from (a) the breast cancer adjuvant data showing reliable estradiol suppression and (b) the general AI-class men's-health rationale shared with the nonsteroidal AIs. Some research-community sources favor exemestane over the nonsteroidal AIs on the rationale that the irreversible mechanism produces more consistent estradiol suppression across imperfect dosing schedules and that the mild androgenic activity is theoretically beneficial in men — but neither claim is RCT-validated.

Regulatory status. Exemestane was FDA-approved (NDA 020753) on October 21, 1999, for advanced postmenopausal breast cancer. The adjuvant indication followed in 2005. Generic exemestane became widely available in 2011 after US patent expiry. Listed by name in the 2026 WADA Prohibited List under Section S4.1 (Aromatase Inhibitors) as a Specified Substance[⁵] — researchers competing in WADA-tested sport should not use exemestane.

Commonly reported

• Hot flashes (~33% of patients, comparable to letrozole and anastrozole)
• Arthralgia and joint stiffness (~18–20%, slightly less than letrozole and anastrozole per some comparative analyses)
• Fatigue (~16%)
• Headache (~13%)
• Nausea (~9%)
• Insomnia (~9%)
• Increased sweating (~6%)
• Hypercholesterolemia (~5–10%)
• Skeletal events (osteopenia, fractures — increased over multi-year courses, comparable to letrozole and anastrozole)
• Mild androgenic-pattern side effects in some women (acne, mild hirsutism — uncommon, attributable to the steroidal backbone's weak androgenic activity)

Serious

• Severe joint pain or new arthralgia preventing daily activity
• Symptoms of bone loss or non-traumatic fracture
• Severe mood disturbance, depression, or suicidal ideation
• Cardiovascular events or new chest pain
• Significant elevation in cholesterol or lipid panel
• Severe persistent fatigue or weakness

Premenopausal women — FDA labeling specifies postmenopausal use; premenopausal women have intact ovarian estradiol synthesis that is not adequately suppressed by AI alone.

Pregnancy — Pregnancy Category D. Contraindicated; teratogenic in animal models. Women of reproductive potential should use effective contraception during use and for 1 month after the last dose.

Lactation — contraindicated.

Severe hepatic impairment — exemestane is hepatically metabolized via CYP3A4; dose adjustment may be needed in severe hepatic impairment.

Severe renal impairment — exemestane pharmacokinetics in severe renal impairment have not been fully characterized; caution.

Severe osteoporosis or known osteopenia — caution; AIs accelerate bone loss. Baseline DEXA and ongoing monitoring are recommended.

Concurrent CYP3A4 inducers (rifampin, St. John's wort, phenytoin, carbamazepine) — may reduce exemestane levels; consider alternative AI or dose adjustment.

Concurrent estrogen-containing therapies — pharmacologically counterproductive.

Regulatory note (US): Exemestane is FDA-approved for postmenopausal breast cancer indications (advanced and adjuvant). All use in men, premenopausal women, and adolescents is off-label.

Regulatory note (WADA): Exemestane is listed by name in the 2026 WADA Prohibited List under Section S4.1 (Aromatase Inhibitors) as a Specified Substance.[⁵] Researchers competing in WADA-tested sport should not use exemestane.

Aromatase inhibitor

A drug that blocks the aromatase enzyme, which converts androgens into estrogen, thereby lowering estrogen levels.

Off-label use

Use of an approved drug for a condition or population not listed on its FDA-approved label.

Estradiol

The main form of estrogen; relevant in men because some testosterone is converted to estradiol.

Testosterone replacement therapy (TRT)

Medically supervised use of testosterone to treat men with diagnosed low testosterone.

1. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C; Intergroup Exemestane Study. (2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine, 350(11):1081-92.(PMID 15014181)
2. US Food and Drug Administration. Aromasin (exemestane) Prescribing Information. Manufacturer: Pfizer (originally Pharmacia). NDA 020753, originally approved October 21, 1999 (advanced breast cancer); subsequent supplemental approvals for adjuvant indication. FDA Orange Book and
3. Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H; ncic ctg map.3 Study Investigators. (2011). Exemestane for breast-cancer prevention in postmenopausal women. New England Journal of Medicine, 364(25):2381-91.(PMID 21639806 · NCT00083174)
4. Smith IE, Dowsett M. (2003). Aromatase inhibitors in breast cancer. New England Journal of Medicine, 348(24):2431-42.(PMID 12802030)
5. World Anti-Doping Agency. The 2026 Prohibited List, International Standard (effective 1 January 2026). Canonical PDF: wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf (linked from the WADA landing page at wada-ama.org/en/prohibited-list; local archival copy in `docs/legal/wada-2026-prohibited-list.pdf`). Exemestane is listed by name under Section S4.1 (Aromatase Inhibitors) as a Specified Substance alongside anastrozole, letrozole, aminoglutethimide, and other named AIs.

• Testosterone — discussed together in this entry's stacks section
• Clomiphene / Enclomiphene — discussed together in this entry's stacks section
• Anastrozole — same mechanism class
• Letrozole — same mechanism class